|
“Together, we need to create a framework for equity-based tiered pricing to ensure that the price of innovative medicines can vary between countries, depending on their economic level and ability to pay.” Says Lars Fruergaard Jørgensen, Novo Nordisk president and CEO, and EFPIA vice-president to The Economist.
There are significant differences in patients’ access to medicines across Europe. How quickly a patient can benefit from a new treatment is more likely to be based on where they live, rather than on what they need. Faster, more equitable access to medicines across Europe has become a key priority for the research-based pharma industry and policymakers alike.
|
